Join
Live feed
·
PRReleasevia Quantisnow
DICE Therapeutics Inc. logo

DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

ByQuantisnow·Wall Street's wire, on your screen.
DICE· DICE Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DICE (DICE Therapeutics Inc.) and more on Quantisnow.